The combination of PI3K/AKT signaling pathway inhibitor and regorafenib could enhance the curative effect of regorafenib on HCC by inhibiting the proliferation and promoting apoptosis of HCC cells [20, 21]. Here, AKT1 is linked to hepatocellular carcinoma.